Coronavirus (COVID-19) Collection
TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study
After two years into the pandemic, COVID-19 still poses an imminent global threat (Meyer et al., 2020). As of April 2022, 6.1 million people have died from or with an infection of SARS-CoV-2 (https://coronavirus.jhu.edu/, accessed April 2022) worldwide. With vaccination campaigns running slow (Papan et al., 2021), increasing numbers of vaccine breakthrough infections, and a surge of variants of concern with possible immunevasion (Juthani et al., 2021), the pandemic will most likely continue until the most dominant variants eventually become endemic (Boehm et al., 2021).Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
COVID-19 caused by SARS-CoV-2 is currently a challenging pandemic that has caused drastic impacts on health systems and economy worldwide. A severe form of pneumonia, potentially evolving towards acute respiratory distress syndrome (ARDS) and occasionally associated with multiorgan failure, is the leading complication of the respiratory virus (Zaninotto et al., 2020).Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
The deleterious impact of the hyperactive immune response triggered by SARS-CoV-2 has been reported since the start of the pandemic (Giamarellos-Bourboulis et al., 2020, Vabret et al., 2020). Therapeutic immunomodulation emerged as a potentially life-saving option for patients with severe COVID-19 (Luis et al., 2021). Available drugs inhibiting the pleiotropic proinflammatory cytokine interleukin 6 (IL-6) rapidly became of particular interest because elevated IL-6 levels seemed to mediate systemic inflammatory responses associated with SARS-CoV-2 infection and the development of acute respiratory distress syndrome (ARDS) and multiorgan failure (McGonagle et al., 2020).Influence of chronic use of corticosteroids and calcineurin inhibitors on COVID-19 clinical outcomes: analysis of a nationwide registry
Since the beginning of 2020, the world has faced the coronavirus disease 2019 (COVID-19) pandemic. As of November 11, 2021, more than 250 million people had contracted COVID-19 worldwide, and more than 5 million had died (Dong et al., 2020).Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities
Streptococcus pneumoniae remains the most common cause of community-acquired pneumonia (Van der Poll and Opal, 2009; Johansson et al., 2010). Among pneumonia pathogens, it is the leading cause of hospitalization and death in adults (Roson et al., 2001; Shariatzadeh et al., 2005). Approximately 15–25% of cases of pneumococcal pneumonia are bacteraemic (Said et al., 2013), and bacteraemic pneumococcal community-acquired pneumonia (B-PCAP) has traditionally been considered an invasive form of infection related to higher inflammatory status, worse in-hospital course and shorter long-term survival (Capelastegui et al., 2014; Ishiguro et al., 2016; Ruiz et al., 2019).SARS-CoV-2 rapid antigen testing in the healthcare sector: A clinical prediction model for identifying false negative results
Since its onset (Zhu et al., 2020), the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged to a major burden for the population in general but especially brought great challenges for the healthcare sector (Miller et al., 2020). Recent statistics presented by the German federal government agency Robert-Koch-Institute (RKI) show that cough, fever, nasal congestion, sore throat and loss of smell or taste are the most common symptoms caused by COVID-19 (RKI, 2021a).Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection
Most of our understanding of MIS-A is based on various case reports and case series shared by the CDC and published in the medical literature (Bastug et al., 2021; Morris et al., 2020). Here we describe a case of MIS-A in a patient admitted to the Creighton University Medical Center —Bergan Mercy campus in Omaha, Nebraska with clinical presentation and diagnostics suggestive of MIS-A.Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exerted enormous relentless pressures on the global healthcare systems. As of February 4, 2021, over 102 million people were infected with SARS-CoV-2, and more than 2.2 million have died since the start of the pandemic (WHO, 2020). The true number of cases may even exceed the number of diagnosed cases by more than 10-fold (Havers et al., 2020; Stringhini et al., 2020).
